Menveo Dosing and Administration1
- Menveo is supplied in two vials that must be combined prior to administration
- Menveo must be prepared for administration by reconstituting the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component, as described below
- Menveo should be administered as an intramuscular injection, preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle (upper arm) in toddlers, adolescents, and adults1
- Do not administer Menveo intravenously, subcutaneously, or intradermally
The dosing schedule for individuals initiating vaccination is as follows1:
Infants 2 months of age
Children 7 months through 23 months of age
- Menveo is to be administered as a four-dose series at 2, 4, 6, and 12 months of age
Children 2 years through 10 years of age
- Menveo is to be administered as a two-dose series, with the second dose administered in the second year of life and at least three months after the first dose
Adolescents and adults 11 years through 55 years of age
- Menveo is to be administered as a single dose. For children 2 years through 5 years of age at continued high risk of meningococcal disease, a second dose may be administered 2 months after the first dose
- Menveo is to be administered as a single dose
Indication and Important Safety Information
Menveo (Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menveo is approved for use in persons 2 months through 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.
Severe allergic reaction (eg, anaphylaxis) after a previous dose of Menveo, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine is a contraindication to administration of Menveo. Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of Menveo.
Syncope, sometimes resulting in falling injury associated with seizure-like movements, has been reported following vaccination with Menveo. Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions.
Safety and effectiveness of Menveo have not been evaluated in immunocompromised persons. If Menveo is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.
Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer Menveo to subjects with a known history of GBS should take into account the potential benefits and risks.
Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including Menveo, to an infant born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.
In clinical trials, common solicited adverse reactions with Menveo among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea. Common solicited adverse reactions among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea. Common solicited adverse reactions among children 2 years through 10 years of age were injection-site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults were pain at the injection site, headache, myalgia, malaise, and nausea. Some events were severe. Safety has not been established in pregnant women. Vaccination with Menveo may not protect all individuals.
Before administering Menveo, please see full Prescribing Information.
Novartis Vaccines maintains a pregnancy registry to monitor the fetal outcomes of pregnant women exposed to Menveo.
To enroll in the registry or for further information, please call 1-877-311-8972 or click here.
Menveo [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc.; 2013.